Cyrona Cell uses Wharton’s Jelly mesenchymal cells that have been derived from infant umbilical cords as they can:

As Alzheimer’s disease is a debilitating neuropsychiatric disorder that affects the brain, the aim of cell therapy is to preserve what neurological function remains, repair and regenerate areas of damage, and to prevent amyloid beta and tau proteins from wreaking further damage and enable the brain to heal.
Scientifically-Proven Results
|
University/Centre |
Results |
|
|
2011 |
Slovak Academy of Sciences, Slovak Republic |
Helped neurons survival, increased the ability of cells to convert nutrients into energy and increase the firing rate of neurons, caused cells to transform into neurons, and increased the formation of neural nerves. |
|
2012 |
Biomedical Research Institute, South Korea |
Increased the production of an enzyme (neprilysin) that degrades amyloid beta and decreased amyloid beta plaques. |
|
2012 |
University of Eastern Finland, Finland |
Decreased amyloid beta production. |
|
2012 |
First Affiliated Hospital of Soochow University, China |
Improved spatial memory, increased neurotransmitter (acetylcholine) levels, and increased the formation of neural nerves. |
|
2013 |
Tsinghua University, China |
Significantly decreased amyloid beta production, restored learning and memory functions, and increased the brain's ability to heal by producing more microglia. |
|
2013 |
Stem Cell Neuroplasticity Research Group, South Korea |
Significantly decreased amyloid beta production and increased the amount of key proteins that help synapses form. |
|
2013 |
Second Hospital of Shandong University, China |
Improved cognitive function, increased the production of proteins that help synapses form (synapsin I), and significantly decreased amyloid beta production. |
|
2015 |
Yonsei University College of Medicine, South Korea |
Modulated inflammation and increased the brain's ability to heal by producing more microglia as well as decreased the tau and amyloid beta production. |
|
2017 |
The Second Hospital of Shandong University and Jinan Central Hospital, China |
Significantly improved spatial learning and decreased memory decline. |
|
2017 |
Kunming Medical University, China |
Improved early cognitive functions and daily living activities. |
|
2018 |
Yonsei University College of Medicine, South Korea |
Facilitated significant cognitive recovery. |
Achieving high standards in our work is of paramount importance to us. As such, we only produce and use premium grade passage 1 (P1) and passage 2 (P2) Wharton’s Jelly mesenchymal stem cells in all our therapy programmes. These cellular products have also been thoroughly screened and analysed in accordance with the requirements of The International Society for Cellular Therapy prior to use.
We also use the latest in cellular research and technologies to tailor our therapy programmes according to the needs of the individual. Furthermore, our microbiology and clinical team as well as our extensively experienced board-certified physicians are geared towards your safety and wellbeing.
All our therapy programmes are conducted using premium grade P1 and P2 Wharton’s Jelly mesenchymal cells and by board-certified experienced specialists. All patients are also provided with pre-transfusion analysis reports of any and all cellular and supplementary products used during treatment.
International patients will be provided with airport transfer services and accommodations as well as in-city transportation to and from every therapy session.
As no two people are alike, our specialists review each patient’s medical reports before developing the best treatment protocol to addresses their unique needs. Therefore, before speaking to one of our Customer Service Representatives, it is best to have the following handy:
Download our eBook and receive our weekly in-depth and exclusive newsletter about Alzheimer’s Disease.